search
for
 About Bioline  All Journals  Testimonials  Membership  News


Medicina
Croatian Medical Association - Rijeka branch
ISSN: 0025-7729
Vol. 43, No. 2, 2007, pp. 143-149
Bioline Code: me07020
Full paper language: Croatian
Document type: Review Article
Document available free of charge

Medicina, Vol. 43, No. 2, 2007, pp. 143-149

 en Treatment Of Hepatitis C
Štimac, Davor; Luzer, Jelena & Milić, Sandra

Abstract

It is estimated that the number of hepatitis C virus (HCV) infected patients all round the world amounts to 170 million persons and it is likely to expect that the disease progression from acute to chronic ranges between 55% – 85%. The paper sets out the present knowledge on hepatitis C therapy, compares and contrasts the existing treatment methods, points at the disease side effects and offers an insight into a future therapy trends. Nowadays, the standard HCV infection is cured by pegylated interferon and ribavirin within 24 – 48 weeks, depending on the genotype and viral response. Some special categories of patients require modified therapy. In future it is assumed that a number of new medicines, such as specific inhibitors and particularly vaccines are going to be developed thus enabling a more efficient treatment of HCV infected patients.

Keywords
hepatitis C virus (HCV); pegylated interferon; ribavirin; side effects

 
 hr Liječenje Hepatitisa C
Štimac, Davor; Luzer, Jelena & Milić, Sandra


Procjenjuje se da je u svijetu približno 170 milijuna ljudi zaraženo hepatitis C virusom (HCV), a razvoj bolesti iz akutnoga oblika u kronični oblik može se očekivati u 55% do 85% bolesnika. U radu prikazane su dosadašnje spoznaje o terapiji hepatitisa C, uspoređene su postojeće mogućnosti, ukazano je na dosad poznate nuspojave, te je dan uvid u terapiju hepatitisa C u budućnosti. U današnje vrijeme ustaljena terapija HCV infekcije jesu pegilirani interferon i ribavirin u trajanju od 24 tjedna do 48 tjedana, ovisno o genotipu i viralnu odgovoru. U posebnih skupina bolesnika terapija se prilagođuje. U budućnosti očekuje se razvitak novih lijekova, poput specifičnih inhibitora i cjepiva koji će upotpuniti dosadašnje spoznaje i unaprijediti liječenje infekcije HCV-om.


hepatitis C virus (HCV); pegilirani interferon; ribavirin; nuspojave

 
© © 2007 - Croatian Medical Association - Rijeka branch
Alternative site location: http://hrcak.srce.hr/medicina

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil